Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FTC (US Federal Trade Commission) approves AmeriPath sale, shareholders rebel:

This article was originally published in Clinica

Executive Summary

The US Federal Trade Commission has given antitrust clearance to the acquisition of genomic and cancer diagnostic services group AmeriPath by buy-out firm Welsh Carson Anderson & Stowe. WCAS unit Amy Acquisition is offering $21.25 per share in cash and to assume $172m of debt. Shareholders with a combined stake of about 4.5% have filed a lawsuit against the firm's directors on the grounds that the price is too low and not in shareholders' interests. AmeriPath's share is currently trading at $21.60; it was selling for $16.45 immediately before the offer was made in December.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT060872

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel